Clinical value of Tirofiban in the treatment of patients with acute stroke after thrombolytic reocclusion
Objective To investigate the therapeutic value of Tirofiban in patients with acute stroke who were re-blocked after thrombolytic therapy. Methods A total of 106 patients with acute stroke who were treated in our hospital after thrombolytic therapy and re-blocked were enrolled in this study from March 2020 to March 2022. According to the different treatment methods were divided into two groups, each group 53 cases. The two groups were given conventional basic treatment, while the control group and the observation group were given enoxparin sodium injection and Tirofiban hydrochloride injection, respectively. The efficacy, clotting function 24 h after thrombolysis, National Institutes of Health Stroke Scale (NIHSS) score and the incidence of adverse events were compared between the two groups. Results The total effective rate of the observation group (96.23％) was higher than that of the control group (79.25％), and the difference was statistically significant (P＜0.05). 24 h after thrombolysis, there was no significant difference in coagulation function between the two groups (P＞0.05). The NIHSS score of the observation group was lower than that of the control group at 24 h and 7 d after thrombolysis, and the difference was statistically significant (P＜0.05). There was no significant difference in the occurrence of adverse events between the two groups (P＞0.05). Conclusion The application of Tirofiban in acute stroke patients with re-occlusion after thrombolytic therapy can improve the neurological function, improve the therapeutic effect, and high safety.
万方数据
